The Digital Diabetes Patient Reminder Tool for Adults With Type 2 Diabetes: Protocol for a Proof-of-Concept Randomized Controlled Trial.

JMIR Res ProtocSep 22, 2026 (epub)
Clinical ResearchEndocrinology

Barbara Annancy, Steve Van den Bulck, Steffen Fieuws et al.

✦ AI-curated · Sources linked

In 30 seconds

This proof-of-concept randomized controlled trial investigates the Digital Diabetes Patient Reminder (DIPAR) tool's effectiveness in improving diabetes follow-up adherence among adults with type 2 diabetes in Belgium. The primary outcome measures the proportion of patients receiving at least one documented annual albuminuria measurement in electronic medical records. The study aims to recruit approximately 200 participants.

Key findings

  • The primary objective is to increase the proportion of adults with T2DM receiving at least one documented annual albuminuria measurement.
  • The secondary objective assesses the increase in patients with at least 2 documented HbA1c measurements within 12 months.
  • Usability and acceptability of the DIPAR tool will be evaluated through various qualitative methods.

Why it matters

Improving adherence to diabetes monitoring is crucial for preventing complications associated with type 2 diabetes. Digital tools like DIPAR may enhance patient engagement and communication with healthcare providers, potentially leading to better health outcomes.

Source

PubMed · PMID 42771875

Published in JMIR Res Protoc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.